Drug record
What four public record sets show for apixaban. Saved Nov 10, 2026.
| Shortage | Not on the FDA shortage list | Details |
|---|---|---|
| Pharmacy cost | Brand prices only, see table | Details |
| Medicare Part D, 2024 | $20.77 billion | Details |
| FDA recall records | 0 | Details |
Whether the FDA lists this drug as in short supply.
The list changes daily, and it covers the national supply. A pharmacy near you can be out of a drug that is not listed, or have one that is. See today's status.
The national average price retail pharmacies pay to buy it (NADAC).
| Product as surveyed | Type | Pharmacy pays | For 30 | Price since |
|---|---|---|---|---|
| ELIQUIS 2.5 MG TABLET | Brand | $5.51 per each | $165.37 | Oct 21, 2026 |
| ELIQUIS 5 MG TABLET | Brand | $5.52 per each | $165.64 | Oct 21, 2026 |
This is not your price. NADAC is the national average that retail pharmacies pay to buy the drug, from the Medicaid survey for the week of Nov 11, 2026. What you pay adds the pharmacy's markup and dispensing fee and depends on your insurance or any discount card. "For 30" is shown only for products priced per tablet or capsule. Brand prices here are before any rebates.
Medicare Part D spending by product, from the latest annual file (2024).
In 2024, Medicare Part D plans and their members paid $20.77 billion for the 1 product below. That is up 109% from $9.94 billion in 2020.
| Product | 2024 spending | People | Per prescription | Per person, year | 2020 spending |
|---|---|---|---|---|---|
| Eliquis Apixaban | $20.77 billion | 4,424,796 | $863.42 | $4,695.12 | $9.94 billion |
Spending is the gross amount paid at the pharmacy by Part D plans and patients, before manufacturer rebates, which can be large for brand drugs. The same person can use more than one product, so people are not added up across rows. A dash means the file suppresses a small number or has no figure for that year.
Recalls reported to the FDA that name this drug.
These are saved records as of Nov 10, 2026; the sources update daily to yearly. For current figures open the live report for apixaban. This page is public-record information, not medical advice.